Equities analysts expect Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) to announce earnings per share (EPS) of ($0.05) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Eyegate Pharmaceuticals’ earnings. Eyegate Pharmaceuticals posted earnings per share of ($0.07) in the same quarter last year, which indicates a positive year over year growth rate of 28.6%. The firm is expected to issue its next earnings results on Friday, August 16th.

According to Zacks, analysts expect that Eyegate Pharmaceuticals will report full year earnings of ($0.13) per share for the current financial year. For the next fiscal year, analysts forecast that the company will post earnings of ($0.23) per share. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Eyegate Pharmaceuticals.

Eyegate Pharmaceuticals (NASDAQ:EYEG) last announced its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported ($0.04) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.05) by $0.01.

In other Eyegate Pharmaceuticals news, insider Stephen From sold 127,355 shares of the firm’s stock in a transaction on Monday, July 15th. The shares were sold at an average price of $0.24, for a total value of $30,565.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Over the last 90 days, insiders sold 166,154 shares of company stock valued at $39,877. 47.50% of the stock is owned by insiders.

EYEG remained flat at $$0.20 during trading on Tuesday. 163,959 shares of the company’s stock traded hands, compared to its average volume of 350,569. The firm has a market capitalization of $9.57 million, a PE ratio of -0.68 and a beta of 2.04. Eyegate Pharmaceuticals has a 52 week low of $0.20 and a 52 week high of $0.64. The firm has a fifty day simple moving average of $0.23.

Eyegate Pharmaceuticals Company Profile

EyeGate Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye. Its proprietary platform technologies consist of crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S) and iontophoresis drug delivery system.

Recommended Story: Hedge Funds – How They Work For Investors

Get a free copy of the Zacks research report on Eyegate Pharmaceuticals (EYEG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Eyegate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.